Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on June 16, 2021, covering events occurring on June 10 and June 11, 2021. The filing primarily addresses the appointment of a new executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation rather than financial performance metrics.
Material Changes
The material change reported is the appointment of Mr. Alexander Mironov as President of the Company, effective June 10, 2021. Mr. Mironov brings over 20 years of experience in pharmaceutical business development, mergers, and acquisitions, having previously served as Chief Business Officer at Covis Pharma.
Management Commentary and Compensation Details
In connection with the appointment, Mr. Mironov entered into an indefinite-term Employment Agreement with the following key terms:
- Base Salary: $500,000 annually.
- Performance Bonus: Target amount of 20% of base salary, subject to Board discretion.
- Restricted Shares: Grant of up to 300,000 shares contingent on sourcing and contributing to the consummation of pharmaceutical deals.
- Stock Options: Options to purchase up to 200,000 shares with a five-year term, vesting in equal monthly tranches over 36 months.
- Severance: Upon termination without cause or resignation for good reason, Mr. Mironov is entitled to 12 months of base salary and continued benefits.
The full text of the Employment Agreement is scheduled to be filed in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2021.
Investor Verification Checklist
- Verify the specific performance milestones required for the vesting of the 300,000 restricted shares in the full Employment Agreement.
- Review the upcoming Form 10-Q for the quarter ended June 30, 2021, to obtain the complete legal text of the Employment Agreement.
- Assess the potential dilution impact of the 200,000 stock options and 300,000 restricted shares on existing shareholders.
- Confirm Mr. Mironov's prior transaction history and specific contributions at Covis Pharma as described in the filing.